TrialPloS one2018

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.

Tadao Akizawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.